Hugel's 'Letibo' Launches Full-Scale Entry into US Market... First Shipment Dispatched

Hugel announced on the 30th that it has shipped the first export volume of its botulinum toxin product Letibo (domestic name Botulex) to the United States.

The first shipment of Hugel's botulinum toxin product 'Retivo' for export to the United States is being dispatched.
[Photo by Hugel]

After receiving the product approval for Letibo from the U.S. Food and Drug Administration (FDA) in February, Hugel held an official launch event in Las Vegas at the end of last month and has been preparing for the U.S. market launch.

Distribution and marketing in the U.S. will be conducted jointly with its partner, Benev. The two companies aim to quickly establish a foothold in the local market starting with this initial shipment. Utilizing Benev’s strong sales network, they plan to rapidly distribute Letibo locally while conducting academic marketing and educational activities targeting medical professionals to communicate the safety and efficacy of Letibo.

A Hugel representative stated, “The U.S. is the largest botulinum toxin market in the world and still holds high growth potential,” adding, “We will work closely with Benev to achieve a 10% market share in the U.S. within three years and grow into a global top-tier company.”

This content was produced with the assistance of AI translation services.